Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G D Demetri

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1989
Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cellsM Nakamura, S Merchav, A Carter, et al.
Oncogene|August 30, 2001
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsD A Tuveson, N A Willis, T Jacks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trialD F Bajorin, C R Nichols, H J Schmoll, et al.
The Journal of Pathology|July 16, 2008
Heterogeneity of kinase inhibitor resistance mechanisms in GISTB Liegl, I Kepten, C Le, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 7, 2013
Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program studyB L Samuels, S Chawla, S Patel, et al.
Transfusion|February 1, 1996
Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collectionsI J Webb, C E Eickhoff, A D Elias, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinibP Reichardt, J-Y Blay, H Gelderblom, et al.
British Journal of Cancer|September 12, 2013
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trialsA L Cesne, I Judson, R Maki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinibK N Ganjoo, V M Villalobos, A Kamaya, et al.
The Journal of Experimental Medicine|June 1, 1996
Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivoJ J Costa, G D Demetri, T J Harrist, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1989
Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cellsM Nakamura, S Merchav, A Carter, et al.
Oncogene|August 30, 2001
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsD A Tuveson, N A Willis, T Jacks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trialD F Bajorin, C R Nichols, H J Schmoll, et al.
The Journal of Pathology|July 16, 2008
Heterogeneity of kinase inhibitor resistance mechanisms in GISTB Liegl, I Kepten, C Le, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 7, 2013
Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program studyB L Samuels, S Chawla, S Patel, et al.
Transfusion|February 1, 1996
Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collectionsI J Webb, C E Eickhoff, A D Elias, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinibP Reichardt, J-Y Blay, H Gelderblom, et al.
British Journal of Cancer|September 12, 2013
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trialsA L Cesne, I Judson, R Maki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinibK N Ganjoo, V M Villalobos, A Kamaya, et al.
The Journal of Experimental Medicine|June 1, 1996
Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivoJ J Costa, G D Demetri, T J Harrist, et al.
Pageof 7